Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 2075-2086

  Nemati, Fariba ^a   Livartowski, Alain ^a   De Cremoux, Patricia ^a   Bourgeois, Yveline ^a   Arvelo, Francisco ^b   Pouillart, Pierre ^a   Poupon, Marie France ^a  

^a INSTITUT CURIE   (France)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; GLUTATHIONE TRANSFERASE; IFOSFAMIDE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CELL DIVISION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ETOPOSIDE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 0034069027     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Loehrer, P. J., Sr. The role of ifosfamide in small cell lung cancer. Semin. Oncol., 23: 40-44, 1996.
2. Loehrer, P. J., Sr., Ansari, R., Gonin, R., Monaco, F., Fisher, W., Sandler, A., and Einhorn, L. H. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J. Clin. Oncol., 13: 2594-2599, 1995.
3. Loehrer, P. J., Sr., Rynard, S., Ansari, R., Songer, J., Pennington, K., and Einhorn, L. Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer. Cancer (Phila.), 69: 669-673, 1992.
4. Loehrer, P. J., Einhorn, L. H., Williams, S. D., Hui, S. L., Estes, N. C., and Pennington, K. Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon. Cancer Treat. Rep., 69: 1359-1363, 1985.
5. Wolf, M., Havemann, K., Holle, R., Gropp, C., Drings, P., Hans, K., Schroeder, M., Heim, M., Dommes, M., Mende, S., et al. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. J. Clin. Oncol., 5: 1880-1889, 1987.
6. Arriagada, R., Le Chevalier, T., Pignon, J. P., Riviere, A., Monnet, I., Chomy, P., Tuchais, C., Tarayre, M., and Ruffie, P. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N. Engl. J. Med., 329: 1848-1852, 1993.
7. Turrisi, A. T. R., Kim, K., Blum, R., Sause, W. T., Livingston, R. B., Komaki, R., Wagner, H., Aisner, S., and Johnson, D. H. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N. Engl. J. Med., 340: 265-271, 1999.
8. Houghton, P. J., Cheshire, P. J., Hallman, J. D., II, Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
9. Flaman, J. M., Frebourg, T., Moreau, V., Charbonnier, F., Martin, C., Chappuis, P., Sappino, A. P., Limacher, I. M., Bron, L., Benhattar, J., et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl. Acad. Sci. USA, 92: 3963-3967, 1995.
10. Sandler, A. B. Etoposide plus ifosfamide plus cisplatin in the treatment of small cell lung cancer. Semin. Oncol., 25: 38-41, 1998.
11. Miyamoto, H., Nakabayashi, T., Isobe, H., Akita, H., Kawakami, Y., Arimoto, T., Asakawa, M., Suzuki, A., Fujikane, T., Shimizu, T., et al. A Phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology, 49: 431-435, 1992.
12. Thomas, F., Arvelo, F., Antoine, E., Jacrot, M., and Poupon, M. F. Antitumoral activity of bombesin analogues on small cell lung cancer xenografts: relationship with bombesin receptor expression. Cancer Res., 52: 4872-4877, 1992.
13. Arvelo, F., Poupon, M. F., Goguel, A. F., Lizard, G., Bourgeois, Y., Arriagada, R., and Le Chevalier, T. Response of a multidrug-resistant human small-cell lung cancer xenografts to chemotherapy. J. Cancer Res. Clin. Oncol., 120: 17-23, 1993.
14. Poupon, M. F., Arvelo, F., Goguel, A. F., Bourgeois, Y., Jacrot, M., Hanania, N., Arriagada, R., and Le Chevalier, T. Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates. J. Natl. Cancer Inst., 85: 2023-2029, 1993.
15. Arvelo, F., Poupon, M. F., Bichat, F., Grossin, F., Bourgeois, Y., Jacrot, M., Bastian, G., and Le Chevalier, T. Adding a reverser (verapamil) to combined chemotherapy overrides resistance in small cell lung cancer xenografts. Eur. J. Cancer, 31A: 1862-1868, 1995.
16. Canitrot, Y., Bichat, F., Cole, S. P., Deeley, R. G., Gerlach, J. H., Bastian, G., Arvelo, F., and Poupon, M. F. Multidrug resistance genes (MRP) and MDR1 expression in small cell lung cancer xenografts: relationship with response to chemotherapy. Cancer Lett., 130: 133-141, 1998.
17. Aas, T., Borresen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., and Lonning, P. E. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med., 2: 811-814, 1996.
18. Safran, H., King, T., Choy, H., Gollerkeri, A., Kwakwa, H., Lopez, F., Cole, B., Myers, J., Tarpey, J., and Rosmarin, A. p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma. Cancer (Phila.), 78: 1203-1210, 1996.
19. Perdomo, J. A., Naomoto, Y., Haisa, M., Fujiwara, T., Hamada, M., Yasuoka. Y., and Tanaka, N. In vivo influence of p53 status on proliferation and chemoradiosensitivity in non-small-cell lung cancer. J. Cancer Res. Clin. Oncol., 124: 10-18, 1998.
20. Galimberti, S., Marchetti, A., Buttitta, F., Carnicelli, V., Pellegrini, S., Bevilacqua, G., and Petrini, M. Multidrug resistance related genes and p53 expression in human non small cell lung cancer. Anticancer Res., 18: 2973-2976, 1998.
21. Kawasaki, M., Nakanishi, Y., Kuwano, K., Yatsunami, J., Takayama, K., and Hara, N. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin. Cancer Res., 3: 1195-1200, 1997.
22. Blandino, G., Levine, A. J., and Oren, M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene, 18: 477-485, 1999.
23. Yamazaki, K., Isobe, H., Hanada, T., Betsuyaku, T., Hasegawa, A., Hizawa, N., Ogura, S., and Kawakami, Y. Topoisomerase II α content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines. Cancer Chemother. Pharmacol., 39: 192-198, 1997.
24. Jain, N., Lam, Y. M., Pym, J., and Campling, B. G. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Cancer (Phila.), 77: 1797-1808, 1996.
25. Giaccone, G., van Ark-Otte, J., Rubio, G. J., Gazdar, A. F., Broxterman, H. J., Dingemans, A. M., Flens, M. J., Scheper, R. J., and Pinedo, H. M. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. Int. J. Cancer, 66: 760-767, 1996.
26. Laurencot, C. M., Scheffer, G. L., Scheper, R. J., and Shoemaker, R. H. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int. J. Cancer, 72: 1021-1026, 1997.
27. Doyle, L. A. Mechanisms of drug resistance in human lung cancer cells. Semin. Oncol., 20: 326-337, 1993.
28. Sharma, R., Singhal, S. S., Srivastava, S. K., Bajpai, K. K., Frenkel, E. P., and Awasthi, S. Glutathione and glutathione linked enzymes in human small cell lung cancer cell lines. Cancer Lett., 75: 111-119, 1993.
29. Hao, X. Y., Bergh, J., Brodin, O., Hellman, U., and Mannervik, B. Acquired resistance to cisplatin and doxorubicin in a small cell lung cancer cell line is correlated to elevated expression of glutathione-linked detoxification enzymes. Carcinogenesis (Lond.), 15: 1167-1173, 1994.
30. Savaraj, N., Wu, C. J., Xu, R., Lampidis, T., Lai, S., Donnelly, E., Solomon, J., and Feun, L. G. Multidrug-resistant gene expression in small-cell lung cancer. Am. J. Clin. Oncol., 20: 398-403, 1997.
31. Kamataki, T., Yokoi, T., Fujita, K., and Ando, Y. Preclinical approach for identifying drug interactions, Cancer Chemother. Pharmacol., 42: S50-S53, 1998.
32. Relling, M. V., McLeod, H. L., Bowman, L. C., and Santana, V. M. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin. Pharmacol. Ther., 56: 503-511, 1994.
33. Kivisto, K. T., Kroemer, H. K., and Eichelbaum, M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br. J. Clin. Pharmacol., 40: 523-530, 1995.
34. Kivisto, K. T., Griese, E. U., Fritz, P., Linder, A., Hakkola, J., Raunio, H., Beaune, P., and Kroemer, H. K. Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. Naunyn-Schmiedebergs Arch. Pharmacol., 353: 207-212, 1996.